Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - adhoc news (73 News)
Country: Germany · Primary market: Germany · EQS NID: 1841405
20 February 2024 08:35PM

General partner of CompuGroup Medical SE & Co. KGaA plans dividend increase


EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Dividend
General partner of CompuGroup Medical SE & Co. KGaA plans dividend increase

20-Feb-2024 / 20:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


General partner of CompuGroup Medical SE & Co. KGaA plans dividend increase

Against the background of the stable financial and earnings position the general partner of CompuGroup Medical SE & Co. KGaA (CGM) intends to sustainably increase the dividend payment to a higher level. Therefore, the general partner plans to propose to the Annual General Meeting to increase the dividend per dividend bearing share to EUR 1.00 for the financial year 2023, compared to a dividend of EUR 0.50 per share for the financial year 2022.

The proposed dividend increase will be on the agenda of the Supervisory Board after the final financial statements for the financial year 2023 are available.

A dividend payment based on the final dividend proposal of the general partner and the Supervisory Board for the financial year 2023 is subject to the approval of the Annual General Meeting as well as further legal requirements.

CompuGroup Medical SE & Co. KGaA will publish the full Annual Report for the financial year 2023 as planned on March 28, 2024.

 

 



End of Inside Information

20-Feb-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1841405

 
End of Announcement EQS News Service

1841405  20-Feb-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1841405&application_name=news&site_id=boersengefluester_html
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.